Revance Therapeutics | Capitale Ordinario

Ordinary Share Capital Cambiamento Data
AbbVie USD 18M 0 2023-09
ALKERMES USD 1.72M 2K 2023-09
Bristol-Myers Squibb USD 292M 0 2023-09
Eli Lilly USD 593.6M 0 2023-09
Merck USD 1.79B 0 2023-09
Neurocrine Biosciences USD 100K 0 2023-09
Pacira USD 46K 0 2023-12
Supernus Pharmaceuticals USD 55K 0 2023-12



Revance Therapeutics Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2024.